Skip to main content
Top
Published in: BMC Infectious Diseases 1/2012

Open Access 01-12-2012 | Research article

Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain

Authors: Raquel Ibáñez, Judit Moreno-Crespi, Montserrat Sardà, Josefina Autonell, Montserrat Fibla, Cristina Gutiérrez, Belen Lloveras, María Alejo, Isabel Català, Francesc Alameda, Miquel Casas, F Xavier Bosch, Silvia de Sanjosé

Published in: BMC Infectious Diseases | Issue 1/2012

Login to get access

Abstract

Background

A protocol for cervical cancer screening among sexually active women 25 to 65 years of age was introduced in 2006 in Catalonia, Spain to increase coverage and to recommend a 3-year-interval between screening cytology. In addition, Human Papillomavirus (HPV) was offered as a triage test for women with a diagnosis of atypical squamous cells of undetermined significance (ASC-US). HPV testing was recommended within 3 months of ASC-US diagnosis. According to protocol, HPV negative women were referred to regular screening including a cytological exam every 3 years while HPV positive women were referred to colposcopy and closer follow-up. We evaluated the implementation of the protocol and the prediction of HPV testing as a triage tool for cervical intraepithelial lesions grade two or worse (CIN2+) in women with a cytological diagnosis of ASC-US.

Methods

During 2007-08 a total of 611 women from five reference laboratories in Catalonia with a novel diagnosis of ASC-US were referred for high risk HPV (hrHPV) triage using high risk Hybrid Capture version 2. Using routine record linkage data, women were followed for 3 years to evaluate hrHPV testing efficacy for predicting CIN2+ cases. Logistic regression analysis was used to estimate the odds ratio for CIN2 +.

Results

Among the 611 women diagnosed with ASC-US, 493 (80.7%) had at least one follow-up visit during the study period. hrHPV was detected in 48.3% of the women at study entry (mean age 35.2 years). hrHPV positivity decreased with increasing age from 72.6% among women younger than 25 years to 31.6% in women older than 54 years (p < 0.01).
At the end of the 3 years follow-up period, 37 women with a diagnosis of CIN2+ (18 CIN2, 16 CIN3, 2 cancers, and 1 with high squamous intraepithelial lesions -HSIL) were identified and all but one had a hrHPV positive test at study entry. Sensitivity to detect CIN2+ of hrHPV was 97.2% (95%confidence interval (CI) = 85.5-99.9) and specificity was 68.3% (95%CI = 63.1-73.2). The odds ratio for CIN2+ was 45.3 (95% CI: 6.2-333.0), when among ASC-US hrHPV positive women were compared to ASC-US hrHPV negative women.

Conclusions

Triage of ASC-US with hrHPV testing showed a high sensitivity for the detection of CIN2+ and a high negative predictive value after 3 years of follow-up. The results of this study are in line with the current guidelines for triage of women with ASC-US in the target age range of 25-65. Non adherence to guidelines will lead to unnecessary medical interventions. Further investigation is needed to improve specificity of ASC-US triage.
Literature
1.
go back to reference Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJF, Peto J, Meijer CJLM, Muñoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999, 189: 12-19. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.CrossRefPubMed Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJF, Peto J, Meijer CJLM, Muñoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999, 189: 12-19. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.CrossRefPubMed
2.
go back to reference Ferlay J, Parkin DM, Curado MP: Cancer Incidence in Five Continents. Edited by: International Agency for Research on Cancer. 2010, I to IX: (Accessed April, 2011 http://ci5.iarc.fr) Ferlay J, Parkin DM, Curado MP: Cancer Incidence in Five Continents. Edited by: International Agency for Research on Cancer. 2010, I to IX: (Accessed April, 2011 http://​ci5.​iarc.​fr)
3.
go back to reference IARC Working Group on the Evaluation of Cancer-Preventive Strategies: Cervix Cancer Screening. Edited by: IARC Press. 2005, Lyon, France, 10: IARC Working Group on the Evaluation of Cancer-Preventive Strategies: Cervix Cancer Screening. Edited by: IARC Press. 2005, Lyon, France, 10:
4.
go back to reference Dufresne S, Sauthier P, Mayrand MH, Petignat P, Provencher D, Drouin P, Gauthier P, Dupuis MJ, Michon B, Ouellet S, Hadjeres R, Ferenczy A, Franco EL, Coutlée F: Human Papillomavirus (HPV) DNA Triage of Women with Atypical Squamous Cells of Undetermined Significance with Amplicor HPV and Hybrid Capture 2 Assays for Detection of High-Grade Lesions of the Uterine Cervix. J Clin Microbiol. 2011, 49 (1): 48-53. 10.1128/JCM.01063-10.CrossRefPubMed Dufresne S, Sauthier P, Mayrand MH, Petignat P, Provencher D, Drouin P, Gauthier P, Dupuis MJ, Michon B, Ouellet S, Hadjeres R, Ferenczy A, Franco EL, Coutlée F: Human Papillomavirus (HPV) DNA Triage of Women with Atypical Squamous Cells of Undetermined Significance with Amplicor HPV and Hybrid Capture 2 Assays for Detection of High-Grade Lesions of the Uterine Cervix. J Clin Microbiol. 2011, 49 (1): 48-53. 10.1128/JCM.01063-10.CrossRefPubMed
5.
go back to reference ASCUS-LSIL Triage Study (ALTS) Group: Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 2003, 188 (6): 1383-1392.CrossRef ASCUS-LSIL Triage Study (ALTS) Group: Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 2003, 188 (6): 1383-1392.CrossRef
6.
go back to reference Silverloo I, Andrae B, Wilander E: Value of high-risk HPV-DNA testing in the triage of ASCUS. Acta Obstet Gynecol Scand. 2009, 88 (9): 1006-1010. 10.1080/00016340903160952.CrossRefPubMed Silverloo I, Andrae B, Wilander E: Value of high-risk HPV-DNA testing in the triage of ASCUS. Acta Obstet Gynecol Scand. 2009, 88 (9): 1006-1010. 10.1080/00016340903160952.CrossRefPubMed
7.
go back to reference Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine. 2006, 24 (Suppl 3): S3/78-89. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine. 2006, 24 (Suppl 3): S3/78-89.
8.
go back to reference Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C, Iftner T: Joint European Cohort Study Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008, 13: 337- Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C, Iftner T: Joint European Cohort Study Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008, 13: 337-
9.
go back to reference Cox JT: History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results. J Clin Virol. 2009, 45 (Suppl 1): S3-S12.CrossRefPubMed Cox JT: History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results. J Clin Virol. 2009, 45 (Suppl 1): S3-S12.CrossRefPubMed
10.
go back to reference Ostensson E, Fröberg M, Hjerpe A, Zethraeus N, Andersson S: Economic analysis of human papillomavirus triage, repeat cytology, and immediate colposcopy in management of women with minor cytological abnormalities in Sweden. Acta Obstet Gynecol Scand. 2010, 89 (10): 1316-1325. 10.3109/00016349.2010.512066.CrossRefPubMed Ostensson E, Fröberg M, Hjerpe A, Zethraeus N, Andersson S: Economic analysis of human papillomavirus triage, repeat cytology, and immediate colposcopy in management of women with minor cytological abnormalities in Sweden. Acta Obstet Gynecol Scand. 2010, 89 (10): 1316-1325. 10.3109/00016349.2010.512066.CrossRefPubMed
11.
go back to reference Marcos-Gragera R, Cardó X, Galceran J, Ribes J, Izquierdo A, Borràs J: Cancer incidence in Catalonia, 1998-2002. Med Clin (Barc). 2008, 131 (Suppl 1): 4-10.CrossRef Marcos-Gragera R, Cardó X, Galceran J, Ribes J, Izquierdo A, Borràs J: Cancer incidence in Catalonia, 1998-2002. Med Clin (Barc). 2008, 131 (Suppl 1): 4-10.CrossRef
12.
go back to reference Ascunce N, Salas D, Zubizarreta R, Almazán R, Ibáñez J, Ederra M, representatives of the Network of Spanish Cancer Screening Programmes (Red de Programas Españoles de Cribado de Cáncer): Cancer screening in Spain. Annals of Oncology. 2010, 21 (Supplement 3): iii43-iii51. 10.1093/annonc/mdq085.CrossRefPubMed Ascunce N, Salas D, Zubizarreta R, Almazán R, Ibáñez J, Ederra M, representatives of the Network of Spanish Cancer Screening Programmes (Red de Programas Españoles de Cribado de Cáncer): Cancer screening in Spain. Annals of Oncology. 2010, 21 (Supplement 3): iii43-iii51. 10.1093/annonc/mdq085.CrossRefPubMed
13.
go back to reference Puig-Tintoré LM, Castellsagué X, Torné A, de Sanjosé S, Cortés J, Roura E, Méndez C, Bosch FX: Coverage and factors associated with cervical cancer screening: results from the AFRODITA study: a population-based survey in Spain. J Low Genit Tract Dis. 2008, 12 (2): 82-89. 10.1097/LGT.0b013e3181599c16.CrossRefPubMed Puig-Tintoré LM, Castellsagué X, Torné A, de Sanjosé S, Cortés J, Roura E, Méndez C, Bosch FX: Coverage and factors associated with cervical cancer screening: results from the AFRODITA study: a population-based survey in Spain. J Low Genit Tract Dis. 2008, 12 (2): 82-89. 10.1097/LGT.0b013e3181599c16.CrossRefPubMed
15.
go back to reference Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T, Young N: Forum Group Members Bethesda 2001 Workshop. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002, 287 (16): 2114-2119. 10.1001/jama.287.16.2114.CrossRefPubMed Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T, Young N: Forum Group Members Bethesda 2001 Workshop. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002, 287 (16): 2114-2119. 10.1001/jama.287.16.2114.CrossRefPubMed
16.
go back to reference Bulten J, Horvat R, Jordan J, Herbert A, Wiener H, Arbyn M: European guidelines for quality assurance in cervical histopathology. Acta Oncol. 2011, 50 (5): 611-620. 10.3109/0284186X.2011.555779.CrossRefPubMed Bulten J, Horvat R, Jordan J, Herbert A, Wiener H, Arbyn M: European guidelines for quality assurance in cervical histopathology. Acta Oncol. 2011, 50 (5): 611-620. 10.3109/0284186X.2011.555779.CrossRefPubMed
17.
go back to reference Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D: 2006 ASCCP-Sponsored Consensus Conference: 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis. 2007, 11 (4): 201-222. 10.1097/LGT.0b013e3181585870.CrossRefPubMed Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D: 2006 ASCCP-Sponsored Consensus Conference: 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis. 2007, 11 (4): 201-222. 10.1097/LGT.0b013e3181585870.CrossRefPubMed
18.
go back to reference Apgar BS, Kittendorf AL, Bettcher CM, Wong J, Kaufman AJ: Update on ASCCP consensus guidelines for abnormal cervical screening tests and cervical histology. Am Fam Physician. 2009, 80 (2): 147-155.PubMed Apgar BS, Kittendorf AL, Bettcher CM, Wong J, Kaufman AJ: Update on ASCCP consensus guidelines for abnormal cervical screening tests and cervical histology. Am Fam Physician. 2009, 80 (2): 147-155.PubMed
19.
go back to reference Moscicki AB, Ma Y, Wibbelsman C, Darragh TM, Powers A, Farhat S, Shiboski S: Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol. 2010, 116 (6): 1373-1380. 10.1097/AOG.0b013e3181fe777f.CrossRefPubMedPubMedCentral Moscicki AB, Ma Y, Wibbelsman C, Darragh TM, Powers A, Farhat S, Shiboski S: Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol. 2010, 116 (6): 1373-1380. 10.1097/AOG.0b013e3181fe777f.CrossRefPubMedPubMedCentral
20.
go back to reference Meijer CJ, Berkhof H, Heideman DA, Hesselink AT, Snijders PJ: Validation of high-risk HPV tests for primary cervical screening. J Clin Virol. 2009, 46 (Suppl 3): S1-S4.CrossRefPubMed Meijer CJ, Berkhof H, Heideman DA, Hesselink AT, Snijders PJ: Validation of high-risk HPV tests for primary cervical screening. J Clin Virol. 2009, 46 (Suppl 3): S1-S4.CrossRefPubMed
21.
go back to reference Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, Dillner J, Meijer CJ: Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008, 26 (Suppl 10): K29-K41.CrossRefPubMed Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, Dillner J, Meijer CJ: Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008, 26 (Suppl 10): K29-K41.CrossRefPubMed
22.
go back to reference Diaz M, de Sanjose S, Ortendahl J, O'Shea M, Goldie SJ, Bosch FX, Kim JJ: Cost-effectiveness of human papillomavirus vaccination and screening in Spain. Eur J Cancer. 2010, 46 (16): 2973-2985. 10.1016/j.ejca.2010.06.016.CrossRefPubMed Diaz M, de Sanjose S, Ortendahl J, O'Shea M, Goldie SJ, Bosch FX, Kim JJ: Cost-effectiveness of human papillomavirus vaccination and screening in Spain. Eur J Cancer. 2010, 46 (16): 2973-2985. 10.1016/j.ejca.2010.06.016.CrossRefPubMed
23.
go back to reference Del Mistro A, Frayle-Salamanca H, Trevisan R, Matteucci M, Pinarello A, Zambenedetti P, Buoso R, Fantin GP, Zorzi M, Minucci D: Triage of women with atypical squamous cells of undetermined significance (ASC-US): results of an Italian multicentric study. Gynecol Oncol. 2010, 117 (1): 77-81. 10.1016/j.ygyno.2010.01.003.CrossRefPubMed Del Mistro A, Frayle-Salamanca H, Trevisan R, Matteucci M, Pinarello A, Zambenedetti P, Buoso R, Fantin GP, Zorzi M, Minucci D: Triage of women with atypical squamous cells of undetermined significance (ASC-US): results of an Italian multicentric study. Gynecol Oncol. 2010, 117 (1): 77-81. 10.1016/j.ygyno.2010.01.003.CrossRefPubMed
24.
go back to reference Bhatla N, Moda N: The clinical utility of HPV DNA testing in cervical cancer screening strategies. Indian J Med Res. 2009, 130 (3): 261-265.PubMed Bhatla N, Moda N: The clinical utility of HPV DNA testing in cervical cancer screening strategies. Indian J Med Res. 2009, 130 (3): 261-265.PubMed
25.
go back to reference Luyten A, Scherbring S, Reinecke-Lüthge A, Braun BE, Pietralla M, Theiler K, Petry KU: Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany-experience over 3 years. J Clin Virol. 2009, 46 (Suppl 3): S5-S10.CrossRefPubMed Luyten A, Scherbring S, Reinecke-Lüthge A, Braun BE, Pietralla M, Theiler K, Petry KU: Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany-experience over 3 years. J Clin Virol. 2009, 46 (Suppl 3): S5-S10.CrossRefPubMed
26.
go back to reference Mesher D, Szarewski A, Cadman L, Cubie H, Kitchener H, Luesley D, Menon U, Hulman G, Desai M, Ho L, Terry G, Williams A, Sasieni P, Cuzick J: Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study. Br J Cancer. 2010, 102 (9): 1405-1410. 10.1038/sj.bjc.6605619.CrossRefPubMedPubMedCentral Mesher D, Szarewski A, Cadman L, Cubie H, Kitchener H, Luesley D, Menon U, Hulman G, Desai M, Ho L, Terry G, Williams A, Sasieni P, Cuzick J: Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study. Br J Cancer. 2010, 102 (9): 1405-1410. 10.1038/sj.bjc.6605619.CrossRefPubMedPubMedCentral
Metadata
Title
Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain
Authors
Raquel Ibáñez
Judit Moreno-Crespi
Montserrat Sardà
Josefina Autonell
Montserrat Fibla
Cristina Gutiérrez
Belen Lloveras
María Alejo
Isabel Català
Francesc Alameda
Miquel Casas
F Xavier Bosch
Silvia de Sanjosé
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2012
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-12-25

Other articles of this Issue 1/2012

BMC Infectious Diseases 1/2012 Go to the issue